"AES has the industry expertise in designing and building modular,
validated, cGMP manufacturing suites for pharmaceutical industries,"
said Anil R. Diwan, PhD, President, NanoViricides, Inc., adding, "We are
very pleased to have such experts working with us to enable this project
in a cost effective fashion without compromising on quality or
performance."

As previously announced, this facility will be built by renovating an
existing 18,000 sq. ft. light manufacturing plant on a 4.2 acre lotin
Shelton, CT. AES will be responsible for the critical cGMP manufacturing
suites space. In addition, NanoViricides, Inc. has retained ID3A
architects as the Principal Architect for the project and integration of
the separately constructed Clean Room Suite for cGMP production. Ms.
Kathyann Cowles, AIA, of ID3A joins Mr. Phil Mader of MPH Engineering,
LLC (MPH) , and Mr. Andrew Hahn, to complete our architecture, design
and construction management team. As previously announced, Mr. Hahn
continues to provide overall stewardship of the project, while Mr. Mader
is responsible for detailed project management, and his firm, MPH, is
providing engineering services.

The Company has previously reported about the Shelton light industrial
building that will house the cGMP pilot production plant, research
laboratories, and offices. The cGMP pilot plant is being designed for
the production of sufficient quantities of the drug needed for human
clinical trials for each of the various nanoviricides® drug candidates
as they advance into the clinical pipeline.

The light industrial building at 1 Controls Drive, Shelton CT was
purchased by Inno-Haven, LLC. Inno-Haven is a private company that was
founded by Dr. Anil R. Diwan, the Company's CEO, and financed by himself
and certain of his friends and associates, with the specific purpose of
enabling clinical cGMP manufacturing capabilities for NanoViricides,
Inc. drug substances. Acquisition of this 18,000 sqft building on 4.2
acres of land was previously announced by NanoViricides, Inc. in
September, 2011. Renovation of the building is to be performed as per
the requirements of NanoViricides, Inc. for the production of the
nanoviricides drug candidates for clinical trials under cGMP processes.
The drug substance produced in this facility will then be delivered to a
third party for final processing and labeling, as required, for human
clinical trials when ready. NanoViricides, Inc. expects to lease this
facility. No lease has been signed yet and no terms of lease have been
finalized as of now.

NanoViricides,
Inc. (www.nanoviricides.com)
is a development stage company that is creating special purpose
nanomaterials for antiviral therapy. The Company's novel nanoviricide®
class drug candidates are designed to specifically attack enveloped
virus particles and to dismantle them. The Company is developing drugs
against a number of viral diseases including H1N1 swine flu, H5N1 bird
flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of
the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue
fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the
Company's current expectation regarding future events. Actual events
could differ materially and substantially from those projected herein
and depend on a number of factors. Certain statements in this release,
and other written or oral statements made by NanoViricides, Inc. are
"forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934. You should not place undue reliance on forward-looking statements
since they involve known and unknown risks, uncertainties and other
factors which are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no obligation
to publicly update or revise these forward-looking statements for any
reason, or to update the reasons actual results could differ materially
from those anticipated in these forward-looking statements, even if new
information becomes available in the future. Important factors that
could cause actual results to differ materially from the Company's
expectations include, but are not limited to, those factors that are
disclosed under the heading "Risk Factors" and elsewhere in documents
filed by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities. Although it is
not possible to predict or identify all such factors, they may include
the following: demonstration and proof of principle in pre-clinical
trials that a nanoviricide is safe and effective; successful development
of our product candidates; our ability to seek and obtain regulatory
approvals, including with respect to the indications we are seeking; the
successful commercialization of our product candidates; and market
acceptance of our products.

Meet Your Big Data Storage Needs: CoraidAs businesses collect more and more data, they will require storage capabilities that are easily and secure, accessible, and quickly scalable for pure storage as well as data analytics.

Managing Your Data and Apps in Multi-Cloud Environments: Right ScaleBusinesses have reached beyond education and are starting to make signifcant cloud computing deployments, which means they need an awareness of public and private resources, which to deploy in what instances, and how to manage and maintain applications across both domains.

Enabling Cross-border Data Center Connectivity: InterxionOne of the challenges for multinational enterprises is establishing connectivity between infrastructure located on different continents. The Transatlantic Data Center Alliance helps overcome many of these challenges, including regulatory and compliance needs.